Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GDUFA Accounting Challenge Already Felt By FDA, Industry

This article was originally published in The Pink Sheet Daily

Executive Summary

Commissioner Hamburg tells GPhA that if the agency does not get an accurate count of facilities covered by the user fee program, it could under- or over-collect fees, neither of which benefits industry – or even FDA.

You may also be interested in...

Biosimilars, Generic Programs Leave Little Room For Other New FDA Drug Initiatives In FY ‘13

Proposed and existing user fees would fund 44% of the $4.5 billion FDA FY 2013 spending plan. User fees are projected at $20 million for biosimilars and $229 million for generic drugs.

Generic Facility Fee Unlikely To Be Charged Until A Few Months After GDUFA Implementation

FDA will need a bit of time to develop a comprehensive database of all the facilities that produce active pharmaceutical ingredients and finished dosage forms for the U.S. market as part of the proposed generic drug user fee program.

ANDA User Fees Will Fund Public Relations-focused Studies On Palatability Of Generics

One project will look at tablet size, odor and other characteristics that in the past have been a source of public complaints about generics.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts